Skip to content

SUNRISE Trial for Oral Steroid Dependent Asthma

Search Clinical Trials

Trial Objectives


People with severe asthma are often dependent on oral corticosteroids, such as prednisone, to treat their condition. Researchers are currently investigating whether a new biologic treatment called tezepelumab may help to reduce or remove the need for these steroid medications.

In this study, tezepelumab will be compared against a treatment that does not contain any active medication, called a placebo. Either tezepelumab or the placebo will be given as an injection to study participants.
 

Who Can Participate


Adults ages 18-80 with a documented asthma diagnosis for at least 1 year requiring daily oral steroids for at least 6 months in addition to inhaled steroid treatments. Other criteria will be evaluated to see if you may participate in this study.

Age: 18-80 Gender: Any

Estimated Time Commitment


14 visits over approximately 12 months. Most visits will last about 2 hours, but a few could take up to 4 hours.

Payment & Reimbursement


Payment: Provided

Travel Reimbursement: Not Available

Trial Contact


For more information, contact:

Allen Stevens
720-862-6613

Request More Information

Trial Location


National Jewish Main Campus, Denver, CO

Trial Sponsors


AstraZeneca

Principal Investigators

Michael E. Wechsler

Michael E. Wechsler, MD, MMSc

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required